Netazepide

Drug Profile

Netazepide

Alternative Names: YF 476

Latest Information Update: 08 Dec 2015

Price : $50

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; Ferring Pharmaceuticals; Trio Medicines
  • Class
  • Mechanism of Action Cholecystokinin B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Barrett's oesophagus
  • No development reported Gastric cancer; Gastritis
  • Discontinued Gastro-oesophageal reflux; Peptic ulcer; Reflux oesophagitis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 17 Jun 2015 Phase-II clinical trials in Barrett's oesophagus in USA and United Kingdom (PO) (NCT01298999; UKCRN18198)
  • 02 Jun 2015 No development reported - Phase-II for Gastric cancer (Prevention) in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top